TriangleAntiandrogen Therapy (NCT06244004)
Antiandrogen Therapy trial for Castration-Sensitive Prostate Carcinoma (NCT06244004). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic, hormone-sensitive prostate cancer, within the study’s treatment timing limits.
The idea: use an FDG-PET scan after about six months of standard treatment to find cancer that remains active. Those with active sites are randomized to continued standard treatment with or without radiation targeting up to five sites. Radiation aims to kill cancer cells. Those without active sites continue standard treatment. Separate groups receive treatment with or without chemotherapy.
This phase 2 study plans 125 patients. David VanderWeele leads Northwestern’s five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.